Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study.
Sabine Tejpar
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Heinz-Josef Lenz
Consultant or Advisory Role - EMA
Honoraria - Bayer; Bristol-Myers Squibb; Merck; Roche
Claus-Henning Köhne
Consultant or Advisory Role - EMA
Honoraria - Bayer; Bristol-Myers Squibb; Merck KGaA; Roche
Volker Heinemann
Consultant or Advisory Role - Amgen; Merck KGaA; Roche; Sanofi
Honoraria - Amgen; Merck KGaA; Roche; Sanofi
Research Funding - Amgen; Merck KGaA; Roche; Sanofi
Fortunato Ciardiello
Honoraria - Bayer; Merck Serono
Research Funding - AstraZeneca; Bayer; Merck Serono
Regina Esser
Employment or Leadership Position - Merck KGaA
Stock Ownership - Merck KGaA
Frank Beier
Employment or Leadership Position - Merck KGaA
Christopher Stroh
Employment or Leadership Position - Merck Serono
Klaus Duecker
Employment or Leadership Position - Merck Serono
Other Remuneration - Merck Serono
Carsten Bokemeyer
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono